Stephen Kneebone - Olympus Co Officer
| OCPNF Stock | USD 16.00 0.00 0.00% |
Insider
Stephen Kneebone is Co Officer of Olympus
| Phone | 81 3 3340 2111 |
| Web | https://www.olympus-global.com |
Olympus Management Efficiency
The company has return on total asset (ROA) of 0.0815 % which means that it generated a profit of $0.0815 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.2329 %, meaning that it generated $0.2329 on every $100 dollars invested by stockholders. Olympus' management efficiency ratios could be used to measure how well Olympus manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Rajwant Sodhi | ResMed Inc | 46 | |
| F Ball | Alcon AG | 64 | |
| Matt Tomkin | Teleflex Incorporated | N/A | |
| Molly Joseph | West Pharmaceutical Services | 46 | |
| Antoine Ezell | Becton Dickinson and | 51 | |
| Constance Bienfait | ResMed Inc | N/A | |
| Scott Maw | Alcon AG | 53 | |
| Ines Poschel | Alcon AG | 50 | |
| A Bender | The Cooper Companies, | 79 | |
| Mike Wang | Carl Zeiss Meditec | N/A | |
| Kevin Thornal | Hologic | 50 | |
| S Attias | Alcon AG | 52 | |
| Laurie Ferguson | Carl Zeiss Meditec | N/A | |
| Warner H | The Cooper Companies, | 56 | |
| Teresa Madden | The Cooper Companies, | 65 | |
| Kimberly Martin | Alcon AG | 49 | |
| Steven MD | Carl Zeiss Meditec | N/A | |
| Marco Catalani | EssilorLuxottica Socit anonyme | N/A | |
| Ellen Bjurgert | Coloplast A | N/A | |
| Justin Leong | ResMed Inc | 47 | |
| Steven MD | Carl Zeiss Meditec | N/A | |
Management Performance
| Return On Equity | 0.23 | |||
| Return On Asset | 0.0815 |
Olympus Leadership Team
Elected by the shareholders, the Olympus' board of directors comprises two types of representatives: Olympus inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Olympus. The board's role is to monitor Olympus' management team and ensure that shareholders' interests are well served. Olympus' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Olympus' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Stefan Kaufmann, Executive Officer | ||
| Chikashi Takeda, Ex CFO | ||
| Andre Roggan, Ex CTO | ||
| Yasuo Takeuchi, Sr. Executive Managing Officer, Head of Corporate Management Office and Director | ||
| Nacho Abia, Executive Officer | ||
| Stephen Kneebone, Co Officer | ||
| Donna Miller, Head Counsel | ||
| Tetsuo Kobayashi, Executive Officer | ||
| Takaaki Sakurai, VP Relations | ||
| Shigeto Ohtsuki, Co Head |
Olympus Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Olympus a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.23 | |||
| Return On Asset | 0.0815 | |||
| Current Valuation | 25.72 B | |||
| Shares Outstanding | 1.27 B | |||
| Shares Owned By Insiders | 4.42 % | |||
| Shares Owned By Institutions | 59.82 % | |||
| Price To Earning | 29.76 X | |||
| Price To Book | 5.27 X | |||
| Price To Sales | 0.03 X | |||
| Revenue | 868.87 B |
Currently Active Assets on Macroaxis
Other Information on Investing in Olympus Pink Sheet
Olympus financial ratios help investors to determine whether Olympus Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Olympus with respect to the benefits of owning Olympus security.